TKNO Q4 2025 Earnings — Alpha Teknova, Inc. Revenue & Financial Results | Market Cap Arena

TKNOAlpha Teknova, Inc.

$133M

Q4 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$10M+7.8% YoY

Gross Profit

$3M32.5% margin

Operating Income

-$5M-46.2% margin

Net Income

-$5M-47.7% margin

EPS (Diluted)

$-0.09

QoQ Revenue Growth

-4.5%

Cash Flow

Operating Cash Flow

-$362,000

Free Cash Flow

-$710,000

Stock-Based Comp.

$777,000

Balance Sheet

Total Assets

$104M

Total Liabilities

$35M

Stockholders' Equity

$69M

Cash & Equivalents

$6M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$9M	+7.8%
Gross Profit	$3M	$2M	+52.4%
Operating Income	-$5M	-$6M	+18.1%
Net Income	-$5M	-$6M	+16.8%

Revenue Segments

Lab Essentials

$7M68%

Clinical Solutions

$3M27%

Other Product

$435,0004%

Geographic Segments

UNITED STATES

$9M94%

Non-US

$616,0006%